These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 21442641

  • 1. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    Pardanani A.
    Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
    [Abstract] [Full Text] [Related]

  • 2. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A.
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [Abstract] [Full Text] [Related]

  • 3. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A.
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.
    Pardanani A.
    Am J Hematol; 2016 Nov; 91(11):1146-1159. PubMed ID: 27762455
    [Abstract] [Full Text] [Related]

  • 6. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
    Pardanani A.
    Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
    [Abstract] [Full Text] [Related]

  • 7. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A.
    Am J Hematol; 2021 Apr 01; 96(4):508-525. PubMed ID: 33524167
    [Abstract] [Full Text] [Related]

  • 8. Mastocytosis: state of the art.
    Horny HP, Sotlar K, Valent P.
    Pathobiology; 2007 Apr 01; 74(2):121-32. PubMed ID: 17587883
    [Abstract] [Full Text] [Related]

  • 9. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
    Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A.
    Am J Hematol; 2009 Dec 01; 84(12):790-4. PubMed ID: 19890907
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S, Esterbauer H, Binder T, Müllauer L, Haas OA, Sperr WR, Sillaber C, Valent P.
    Leuk Res; 2006 Sep 01; 30(9):1201-5. PubMed ID: 16406018
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P.
    Hematology Am Soc Hematol Educ Program; 2015 Sep 01; 2015():98-105. PubMed ID: 26637707
    [Abstract] [Full Text] [Related]

  • 15. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P.
    Vet Immunol Immunopathol; 2009 Dec 15; 132(2-4):243-50. PubMed ID: 19505729
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
    Ustun C, DeRemer DL, Akin C.
    Leuk Res; 2011 Sep 15; 35(9):1143-52. PubMed ID: 21641642
    [Abstract] [Full Text] [Related]

  • 17. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK, George R, Mathews V, Balasubramanian P, Thomas M, Nair S.
    J Dermatolog Treat; 2013 Dec 15; 24(6):481-3. PubMed ID: 23659595
    [Abstract] [Full Text] [Related]

  • 18. [Systemic mastocytosis].
    Fain O, Stirnemann J, Eclache V, Barete S, Casassus P, Hermine O, Lorholary O.
    Presse Med; 2005 May 14; 34(9):681-7. PubMed ID: 15988348
    [Abstract] [Full Text] [Related]

  • 19. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.
    Blood; 2007 Apr 01; 109(7):3031-41. PubMed ID: 17110460
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL.
    Cancer; 2006 Jul 15; 107(2):345-51. PubMed ID: 16779792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.